用激肽释放酶治疗少弱精子症和弱精子症男性。

Treatment of men with oligoasthenozoospermia and asthenozoospermia with kallikrein.

作者信息

Mićić S, Bila S, Ilić V, Sulović V

出版信息

Acta Eur Fertil. 1985 Jan-Feb;16(1):51-4.

Abstract

A randomised group of 75 men with idiopathic oligoasthenozoospermia and asthenozoospermia were subjected to control study with kallikrein. Kallikrein was given to 45 men 600 units daily in a period of 3-6 months. The other group of 30 infertile men was followed during the same period of time. Percentage of motile sperm was significantly improved after 3-6 months treatment with kallikrein. Sperm count and percentage of morphologically normal sperm showed improvement but was not statistically significant. Infertile men with sperm count below 20 X 10(6)/ml had greater improvement in sperm count than men with sperm count over 20 X 10(6)/ml. This study emphasizes that kallikrein is a relatively good drug for restoring sperm motility in idiopathic oligoasthenozoospermia and asthenozoospermia.

摘要

75名患有特发性少弱精子症和弱精子症的男性被随机分组，接受了激肽释放酶对照研究。45名男性每天接受600单位激肽释放酶治疗，为期3至6个月。另一组30名不育男性在同一时期接受随访。激肽释放酶治疗3至6个月后，活动精子百分比显著提高。精子计数和形态正常精子百分比有所改善，但无统计学意义。精子计数低于20×10⁶/ml的不育男性精子计数的改善程度大于精子计数超过20×10⁶/ml的男性。这项研究强调，激肽释放酶是恢复特发性少弱精子症和弱精子症患者精子活力的一种相对较好的药物。